Nicholas P. Restifo
National Institutes of Health
419 Papers
6.1K Citations
Nicholas P. Restifo is an academic researcher from National Institutes of Health. The author has contributed to research in topics: T cell & Cytotoxic T cell. The author has an hindex of 140, co-authored 408 publications. Previous affiliations of Nicholas P. Restifo include Government of the United States of America & Memorial Sloan Kettering Cancer Center.
Chat about Author
Papers
Cancer immunotherapy: moving beyond current vaccines.
TL;DR: Results in cancer vaccine trials are considered and alternate strategies that mediate cancer regression in preclinical and clinical models are highlighted.
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley,John R. Wunderlich,Paul F. Robbins,James Chih-Hsin Yang,Patrick Hwu,Douglas J. Schwartzentruber,Suzanne L. Topalian,Richard M. Sherry,Nicholas P. Restifo,Amy M. Hubicki,Michael R. Robinson,Mark Raffeld,Paul H. Duray,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Sharon Mavroukakis,Donald E. White,Steven A. Rosenberg +18 more
TL;DR: The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan,Mark E. Dudley,John R. Wunderlich,Michael S. Hughes,James Chih-Hsin Yang,Richard M. Sherry,Richard E. Royal,Suzanne L. Topalian,Udai S. Kammula,Nicholas P. Restifo,Zhili Zheng,Azam V. Nahvi,Christiaan R. de Vries,Linda Rogers-Freezer,Sharon Mavroukakis,Steven A. Rosenberg +15 more
TL;DR: The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
Adoptive cell transfer as personalized immunotherapy for human cancer.
TL;DR: The ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.
2.3K
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy
Steven A. Rosenberg,James Chih-Hsin Yang,Richard M. Sherry,Udai S. Kammula,Michael S. Hughes,Giao Q. Phan,Deborah Citrin,Nicholas P. Restifo,Paul F. Robbins,John R. Wunderlich,Kathleen E. Morton,Carolyn M. Laurencot,Seth M. Steinberg,Donald E. White,Mark E. Dudley +14 more
TL;DR: Cell transfer therapy with autologous TILs can mediate durable complete responses in patients with metastatic melanoma and has similar efficacy irrespective of prior treatment.